For women living with hormone receptor-positive breast cancer, every tool that lowers risk matters. A new analysis looked at how common cholesterol drugs called statins affect these patients. The researchers combined data from many studies to get a clear picture of what happens when people take these medications. They found that statin use was linked to a 23 percent lower risk of the cancer coming back. This group also saw a significant drop in the risk of dying from the disease. The study looked at nearly 270,000 people to reach these conclusions. This large number of participants gives the results strong weight. The findings suggest that taking a statin could be an extra layer of protection for these patients. The data shows a clear benefit for both stopping the cancer from returning and keeping patients alive longer. While more research is always good, this evidence is solid enough to discuss with your doctor. It is important to remember that this is about general trends in large groups. Your own health history is unique. Always talk to your medical team before starting or stopping any medicine. They can help you decide if a statin is right for your specific situation.
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77Statins lower recurrence and death risk in hormone receptor-positive breast cancer
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note that statin use is associated with lower recurrence and mortality in HR+ breast cancer.
This systematic review and meta-analysis examined the association between statin use and clinical outcomes in patients with hormone receptor-positive breast cancer. The analysis included a total sample size of 267,913 individuals. The primary outcomes assessed were recurrence and mortality. The comparator group consisted of non-users of statins.
The pooled results indicated a 23% reduction in recurrence risk with a hazard ratio of 0.77. The 95% confidence interval for this effect was 0.61–0.98 and the P value was 0.03. For mortality, the analysis demonstrated a significant decrease with a hazard ratio of 0.77. The 95% confidence interval for mortality was 0.73–0.81 and the P value was less than 0.001.
Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported in the source. The authors did not report on causality or certainty notes. The practice relevance suggests that statin therapy confers a protective effect against recurrence and mortality in this patient population.
What this means for you:
Statins lower recurrence and death risk in hormone receptor-positive breast cancer patients. More on Hormone Receptor-Positive Breast Cancer
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
Research in coronary heart disease shows misalignment between investment and clinical guideline priorities
China's heart disease research focuses on bioequivalence, not innovation
This guideline-based research trend analysis of 3,339 publications identifies a significant gap between current research investments and cli…
A review of 3,339 publications shows China's coronary heart disease research heavily emphasizes bioequivalence studies over innovative drug …
Microcirculatory dysfunction during cardiac surgery remains heterogeneous and inconclusive in current clinical evidence
Microcirculation in Cardiac Surgery: What We Know and What Remains Unclear
This narrative review examines microcirculatory dysfunction in patients undergoing cardiac surgery with cardiopulmonary bypass. The authors …
A review of cardiac surgery research shows mixed results on microcirculation, with many gaps between lab findings and patient care.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
View Original Abstract ↓
BackgroundStatins are increasingly recognized for their potential to reduce endocrine therapy resistance and improve overall survival in breast cancer. However, their specific prognostic impact on hormone receptor-positive (HR+) breast cancer remains incompletely understood. This study aims to evaluate the effect of statin use on recurrence and mortality in HR+ breast cancer patients through a comprehensive meta-analysis.MethodsWe systematically searched PubMed, Medline, Cochrane Library, Embase, and Web of Science for studies comparing the outcomes of statin users versus non-users among HR+ breast cancer patients. Hazard ratio (HR) and 95% confidence intervals (CIs) were pooled using appropriate statistical models.ResultsThe meta-analysis incorporated 7 studies encompassing 267,913 HR+ breast cancer patients. Pooled analyses demonstrated that statin use was significantly associated with a 23% reduction in recurrence risk (HR = 0.77; 95% CI: 0.61–0.98, P = 0.03) and a significant decrease in mortality (HR = 0.77; 95% CI: 0.73–0.81, P < 0.001). Sensitivity analyses confirmed the robustness of these findings.ConclusionOur large-scale meta-analysis suggests that statin therapy confers a protective effect against recurrence and mortality in HR+ breast cancer. These findings highlight the promising role of statins as an effective adjunctive therapy and underscore the necessity for future large-scale, prospective trials to optimize their clinical applications.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024599286, identifier CRD42024599286.
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
Related in Oncology
Hepatic MPNST without NF1: normal tumor markers, no recurrence 2 years after resection
Case Report Shows Surgery for Rare Liver Tumor Success
A case report and literature review describes a 56-year-old woman with hepatic malignant peripheral nerve sheath tumor (MPNST) without neuro…
A rare liver tumor known as MPNST was successfully treated with surgery, showing no signs of return after two years.
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer
Expert Review Helps Identify Breast Cancer Spreading to Stomach
This case report describes a 52-year-old woman with metastatic invasive lobular carcinoma that was initially misidentified as primary gastri…
A single patient's case shows how specific lab tests can help doctors distinguish between stomach cancer and metastatic breast cancer.
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC
Trial shows Tucatinib improves progression-free survival for metastatic breast cancer
This Phase III randomized controlled trial of 654 patients with HER2+ metastatic breast cancer found that adding tucatinib to trastuzumab an…
Adding tucatinib to a standard two-drug combination may help patients with HER2+ metastatic breast cancer live longer without their disease …
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…
From Other Specialties
Multi-marker models show higher diagnostic performance than single analytes for identifying recurrent implantation failure
Multi-marker models show promise for diagnosing recurrent implantation failure
This systematic review of 18 studies evaluates fluid-based biomarkers, including blood and uterine fluid, for diagnosing recurrent implantat…
Combining multiple biomarkers may offer a more accurate way to diagnose why some pregnancies fail to implant.
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy
New research explores how inflammation drives nerve damage in diabetes
This narrative review explores the pathophysiology of diabetic peripheral neuropathy, focusing on how hyperglycemia, lipotoxicity, and intes…
Chronic high blood sugar causes more than just high glucose; it triggers a cycle of inflammation and immune stress that damages nerves.
Five core domains of suicide postvention were identified through a Delphi consensus process
Experts agree on core pillars to support suicide survivors
This guideline based on a Delphi consensus study identifies five core domains for suicide postvention: impact/foundations, immediate respons…
A new framework identifies five key areas of care to help people and communities heal after a suicide.
Ultra-processed food consumption is associated with metabolic syndrome, cardiovascular risk, and allergic diseases in children
Ultra-processed foods linked to childhood weight and heart risks
This narrative review synthesizes evidence regarding the impact of ultra-processed food (UPF) on pediatric health. High UPF intake is linked…
High intake of ultra-processed foods is linked to weight gain, metabolic issues, and higher rates of asthma and skin conditions in children.